Patients with ITP who experienced thrombotic events
| Sex . | Age . | Thrombosis type . | Autoimmune markers . |
|---|---|---|---|
| M | 36 | PE | ANA, DAT |
| M | 69 | LE DVT | LAC, ANA |
| M | 34 | PE and DVT | ANA |
| F | 84 | PE and DVT | ANA, anti-ThyPeroxAb |
| M | 54 | Stroke | ANA |
| F | 49 | UE DVT and LE DVT | LAC |
| F | 65 | Superficial LE thrombophlebitis, LE arterial embolism | ANA |
| M | 53 | Superior sagittal sinus thrombosis | ANA |
| M | 81 | PE and LE DVT | ACL IgM, ANA |
| F | 61 | PE | ACL IgM, ANA |
| M | 67 | LE DVT | ANA, DAT |
| F | 56 | LE DVT and MI | LAC, ACL IgG, ANA |
| M | 42 | MI | ANA |
| F | 87 | Distal LE DVT | None |
| F | 21 | Stroke | LAC, ACL IgG, ANA, DAT |
| F | 60 | DVT and PE | ANA, anti-ThyPeroxAb |
| M | 77 | PE and MI | ANA |
| M | 62 | DVT and PE | ANA, DAT |
| F | 66 | Aortic thrombus, multiple arterial thromboemboli, UE DVT | LAC, ANA, RF |
| Sex . | Age . | Thrombosis type . | Autoimmune markers . |
|---|---|---|---|
| M | 36 | PE | ANA, DAT |
| M | 69 | LE DVT | LAC, ANA |
| M | 34 | PE and DVT | ANA |
| F | 84 | PE and DVT | ANA, anti-ThyPeroxAb |
| M | 54 | Stroke | ANA |
| F | 49 | UE DVT and LE DVT | LAC |
| F | 65 | Superficial LE thrombophlebitis, LE arterial embolism | ANA |
| M | 53 | Superior sagittal sinus thrombosis | ANA |
| M | 81 | PE and LE DVT | ACL IgM, ANA |
| F | 61 | PE | ACL IgM, ANA |
| M | 67 | LE DVT | ANA, DAT |
| F | 56 | LE DVT and MI | LAC, ACL IgG, ANA |
| M | 42 | MI | ANA |
| F | 87 | Distal LE DVT | None |
| F | 21 | Stroke | LAC, ACL IgG, ANA, DAT |
| F | 60 | DVT and PE | ANA, anti-ThyPeroxAb |
| M | 77 | PE and MI | ANA |
| M | 62 | DVT and PE | ANA, DAT |
| F | 66 | Aortic thrombus, multiple arterial thromboemboli, UE DVT | LAC, ANA, RF |
F, female; M, male; UE, upper extremity.